Total Payments
$110,241
2022 Payments
$175.54
Companies
13
Transactions
179
Payment Breakdown by Category
Other$84,605 (76.7%)
Travel$12,633 (11.5%)
Consulting$8,715 (7.9%)
Food & Beverage$4,174 (3.8%)
Research$107.00 (0.1%)
Education$6.09 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $84,605 | 47 | 76.7% |
| Travel and Lodging | $12,633 | 38 | 11.5% |
| Consulting Fee | $8,715 | 3 | 7.9% |
| Food and Beverage | $4,174 | 89 | 3.8% |
| Unspecified | $107.00 | 1 | 0.1% |
| Education | $6.09 | 1 | 0.0% |
Payments by Type
General
$110,134
178 transactions
Research
$107.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $50,141 | 87 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $48,321 | 47 | $0 (2020) |
| F. Hoffmann-La Roche AG | $3,839 | 4 | $0 (2019) |
| Millennium Pharmaceuticals, Inc. | $3,600 | 1 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $1,881 | 11 | $0 (2017) |
| Janssen Research & Development, LLC | $1,504 | 19 | $0 (2018) |
| Alkermes, Inc. | $500.33 | 2 | $0 (2017) |
| Biohaven Pharmaceuticals, Inc. | $133.86 | 1 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $120.18 | 1 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $119.80 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $175.54 | 4 | Novartis Pharmaceuticals Corporation ($120.18) |
| 2021 | $148.33 | 2 | Biohaven Pharmaceuticals, Inc. ($133.86) |
| 2020 | $8,461 | 7 | Janssen Pharmaceuticals, Inc ($7,825) |
| 2019 | $51,216 | 55 | Janssen Pharmaceuticals, Inc ($40,496) |
| 2018 | $33,910 | 65 | Allergan Inc. ($33,662) |
| 2017 | $16,330 | 46 | Allergan Inc. ($7,724) |
All Payment Transactions
179 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/01/2022 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $120.18 | General |
| 05/04/2022 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $13.78 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 04/27/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $29.44 | General |
| Category: NEUROSCIENCE | ||||||
| 04/01/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.14 | General |
| Category: NEUROSCIENCE | ||||||
| 11/10/2021 | Biohaven Pharmaceuticals, Inc. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $133.86 | General |
| Category: PRIMARY CARE | ||||||
| 02/25/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: NEUROSCIENCE | ||||||
| 12/15/2020 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Consulting Fee | Cash or cash equivalent | $2,525.00 | General |
| Category: Neuroscience | ||||||
| 11/04/2020 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: Neuroscience | ||||||
| 11/04/2020 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: Neuroscience | ||||||
| 11/03/2020 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $11.46 | General |
| Category: PSYCHIATRY | ||||||
| 02/21/2020 | Allergan, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $625.00 | General |
| 02/14/2020 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: Neuroscience | ||||||
| 01/29/2020 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Neuroscience | ||||||
| 12/31/2019 | Allergan Inc. | VRAYLAR (Drug) | — | Cash or cash equivalent | $107.00 | Research |
| Study: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER • Category: NEUROSCIENCE | ||||||
| 12/06/2019 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: Neuroscience | ||||||
| 11/28/2019 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $171.35 | General |
| Category: Neuroscience | ||||||
| 11/13/2019 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Neuroscience | ||||||
| 11/13/2019 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: Neuroscience | ||||||
| 11/01/2019 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: Neuroscience | ||||||
| 10/30/2019 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: Neuroscience | ||||||
| 10/30/2019 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | In-kind items and services | $607.45 | General |
| Category: Neuroscience | ||||||
| 10/24/2019 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $36.73 | General |
| Category: Neuroscience | ||||||
| 10/23/2019 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | In-kind items and services | $502.88 | General |
| Category: Neuroscience | ||||||
| 10/23/2019 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $101.72 | General |
| Category: Neuroscience | ||||||
| 10/17/2019 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | In-kind items and services | $431.93 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | Allergan Inc. | $107.00 | 1 |
About Dr. Robert Litman, M.D
Dr. Robert Litman, M.D is a Research Study healthcare provider based in Rockville, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/16/2007. The National Provider Identifier (NPI) number assigned to this provider is 1114041274.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Litman, M.D has received a total of $110,241 in payments from pharmaceutical and medical device companies, with $175.54 received in 2022. These payments were reported across 179 transactions from 13 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($84,605).
Ad
Practice Information
- Specialty Research Study
- Location Rockville, MD
- Active Since 03/16/2007
- Last Updated 04/01/2008
- Taxonomy Code 1744R1102X
- Entity Type Individual
- NPI Number 1114041274
Products in Payments
- VRAYLAR (Drug) $49,278
- SPRAVATO (Drug) $48,267
- MK-8189 (Drug) $1,881
- Non-Covered Product (Drug) $1,249
- Aristada 441 mg (Drug) $500.33
- NURTEC ODT (Drug) $133.86
- INVEGA TRINZA (Drug) $53.33
- HETLIOZ (Drug) $13.78
- ABILIFY MAINTENA (Drug) $11.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.